Get in Touch

Quara Devices is introducing its new CEO, Steven Eror, to select investors during the JP Morgan Biotechnology Week in San Francisco.

San Francisco, CA, Jan. 9, 2020 – Quara Devices Inc, is a privately held company with an entirely new technology platform that measures the signature of infectious bacteria, enabling real-time and rapid response in medical, veterinary, pharmaceutical and aquatic applications. Quara Devices is introducing its new CEO, Steven Eror, to select investors at the JP Morgan Biotechnology week in San Francisco. Mr. Eror and his team are developing and commercializing the world’s first Pathogenometer™, QuaraSense™, and its companion product, QuaraView™.

Mr. Eror is a successful CEO, director and investor in public and private companies with achievements in the fields of cancer, inflammation and infection control. He is an award-winning business builder with specific experience in predictive analytics, drug delivery, medical devices, business development, finance, and strategic planning. Mr. Eror, commented, “I have been following the emergence of the Quara Devices technology for some time. I am pleased to join this blue-ribbon team which has distinguished science and engineering as well as innovative financial capability.”

Rod Reum, Quara’s chairman, stated, “Steve has the capability, connections, experience and talent to launch Quara Devices’s novel technology and his arrival brings enthusiasm from the investment community. Coupled with world class science and engineering team capability, we look forward to a new future in infection control.” 

QuaraSense™ will be the world’s first pathogenometer™; hand-held, reusable and reliable. QuaraSense’s patented, early warning technology will be designed to alleviate the overuse of antibiotics in human and animal health, reducing or eliminating the estimated $6 billion-dollar annual losses suffered by the global aquaculture industry due to disease in shrimp, salmon and other food sources and offering rapid, broad pathogen detection for infection control in humans. QuaraView™ will provide tracking data, measuring fluctuations in pathogens over time. For the first time, industry will have the precise information that it needs for intervention in response to weather, feed, treatment or precision process control.  Early disease diagnostics, like QuaraSense and QuaraView will have applications in biosecurity, food chain and medicine.

About the Company

Quara is a private US company launching a novel, proprietary technology platform for human health, animal health, biotechnology and food processing industries.  Its technology is rapid, accurate and handheld and features the QuaraSense and QuaraView product opportunities. Read more HERE.

Quara will also be presenting its Reg D private investment opportunity to selected investors. Click HERE for more information.

Cautionary Statement on Forward Looking Information

Certain information contained in this press release, including any information as to Quara Devices Inc.'s (the "Corporation") strategy, projects, plans or future financial or operating performance, constitutes "forward-looking statements". All statements, other than statements of historical fact, are forward-looking statements. The words "will", "expect", "continue", "assess", "anticipate" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions; including material estimates and assumptions that, while considered reasonable by the Corporation as at the date of this press release in light of each of management's experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information. Any forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Although management of the Corporation believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

For further information contact:  Steven Eror, or 801.631-7288

Key Takeaways
  • QuaraSense™ is an entirely new technology platform that will measure the signature of infectious bacteria, enabling rapid response and greater chance for stopping an infection.
  • QuaraSense™ has been prototyped successfully and is ready for final design and scale up to participate in global markets.
  • Currently a Reg D investment opportunity for accredited investors
Steven Eror
Chief Executive Officer
Media Gallery
Video Gallery
The first handheld sensor to detect bacterial infections in minutes to save lives, alleviate suffering and improve the world’s food supply.
View on Youtube
Steve has the capability, connections, experience and talent to launch Quara Devices’s novel technology and his arrival brings enthusiasm from the ...
Rod ReumChairman of the Board
Related Bios
Steven C. Eror
Chief Executive Officer
View Full Bio>>
Rod Reum, CPA, CGA
Executive Chairman
View Full Bio>>
Nicolette Keith, CPA, CGA
Chief Financial Officer
View Full Bio>>